ОДЖЕР Курт Р. (US),ДАР Мохаммед М. (US),ФЛЕМИНГ Роналд А. (US)
申请号：
RU2014102595/15
公开号：
RU2014102595A
申请日:
2012.06.28
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of the gene product neyrofibromina-2 (NF2) in a sample from said human and administering to said human an effective amount of a focal adhesion kinase inhibitor (FAK), or a pharmaceutically acceptable salts, if not detected or gene product isoform 1 gena.2 product. A method according to Claim. 1 further comprising detecting the phosphorylated FAK (p-FAK) .3. A method according to Claim. 1 further comprising detecting loss of NF2 function isoform 1 gene product if the gene isoform 1 NF2 prisutstvuet.4 product. The method of claim. 3, further comprising administering to said human an effective amount of a FAK inhibitor, or a pharmaceutically acceptable salt, if present detectable amount isoform 1 NF2 gene product and detected the loss of function of one isoform NF2.5 gene product. A method according to Claim. 1, where the presence or absence of the gene product or isoform 1 NF2 gene product is determined using immunohistochemistry (IHC) .6. The method of claim. 5, which comprises using IHC antibody binding isoform 1 NF2 gene product but not other isoforms NF2.7 binding gene product. A method according to Claim. 1 wherein said FAK inhibitor treatment time increases progression free survival (PFS) .8. The method of claim. 7, where the increase in time is a clinically znachimym.9 PFS. The method of claim. 7, where the time increase is statistically znachimym.10 PFS. A method according to Claim. 1, where the sample contains one or more opuholey.11 cells. A method according to Claim. 1, where the NF2 gene product is a protein or function1. Способ лечения злокачественной опухоли у нуждающегося в этом человека, включающий определение присутствия или отсутствия поддающегося детекции количества продукта гена нейрофибромина-2 (NF2) в образце от указанного человека и введение указанному человеку эффективного количества ингибитора киназы фокальной адгези
